

Major HIV-1 Drug Resistance Mutations

Updated Sep 25, 2019

Updated summary from the HIV Drug Resistance Database. This document can be downloaded from the hivdb.stanford.edu home page.



Stanford
HIVDB

Major Nucleoside RT Inhibitor (NRTI) Resistance Mutations													
	Non-TAMs					TAMs						MDR	
	184	65	70	74	115	41	67	70	210	215	219	69	151
Cons	M	K	K	L	Y	M	D	K	L	T	K	T	Q
3TC	<u>VI</u>	R										<u>Ins</u>	M
FTC	<u>VI</u>	R										<u>Ins</u>	M
ABC	VI	R	E	<u>VI</u>	F	L			W	FY		<u>Ins</u>	M
TDF	***	R	E		F	L		R	W	FY		<u>Ins</u>	M
ZDV	***	***	*	*		L	N	R	W	FY	QE	<u>Ins</u>	M

Bold underline: High-level reduced susceptibility or virological response. **Bold**: Reduced susceptibility or virological response. Plain text: Reduced susceptibility in combination with other NRTI-resistance mutations. Asterisk: Increased susceptibility.

TAMs: Thymidine analog mutations. Selected by AZT and d4T and facilitate primer unblocking. Non-TAMs prevent NRTI incorporation.

MDR: Multidrug resistance mutations. T69 insertions occur with TAMs. Q151M occurs with non-TAMs and the accessory mutations A62V, V75I, F77L, and F116Y.

M184VI: The most common NRTI-resistance mutations. Although they cause high-level in vitro resistance to 3TC/FTC, they are not contraindications to 3TC/FTC because they increase TDF and AZT susceptibility and decrease viral replication fitness.

Additional mutations: K65N similar but weaker than K65R. K70GQNT similar to K70E. T69D and V75MT reduce susceptibility to d4T and ddI, which are not shown because they are no longer recommended for HIV treatment. T215SCDEIVALN (T215 revertants) emerge from T215YF in the absence of NRTIs. E40F, E44DA, D67GE, V118I, and K219NR are accessory TAMs. D67, T69, K70 deletions have not been well studied. They usually occur in combination with K65R and/or Q151M.

References: hivdb.stanford.edu/s/nrtinotes

Major Non-Nucleoside RT Inhibitor (NNRTI) Resistance Mutations									
	100	101	103	106	181	188	190	230	
Cons	L	K	K	V	Y	Y	G	M	
DOR	I	EP		<u>AM</u>	CIV	<u>LCH</u>	<u>SE</u>	<u>L</u>	
EFV	<u>I</u>	<u>EP</u>	<u>NS</u>	<u>AM</u>	CIV	<u>LCH</u>	<u>ASEQ</u>	<u>L</u>	
ETR	<u>I</u>	<u>EP</u>			<u>CIV</u>	L	<u>ASEQ</u>	<u>L</u>	
RPV	<u>I</u>	<u>EP</u>			<u>CIV</u>	<u>L</u>	<u>ASEQ</u>	<u>L</u>	
NVP	<u>I</u>	<u>EP</u>	<u>NS</u>	<u>AM</u>	<u>CIV</u>	<u>LCH</u>	<u>ASEQ</u>	<u>L</u>	

Bold underline: High-level reduced susceptibility or virological response. **Bold**: Reduced susceptibility or virological response. Plain text: Reduced susceptibility in combination with other NNRTI-resistance mutations.

Abbreviations: Doravirine (DOR), efavirenz (EFV), etravirine (ETR), rilpivirine (RPV), nevirapine (NVP).

Additional Mutations: A98G (DOR, EFV, ETR, NVP, RPV); E138GQKR are nonpolymorphic mutations associated with intermediate/high-level RPV resistance. E138A is a polymorphic mutation associated with low-level RPV resistance. P225H (DOR, EFV); F227C is associated with high-level DOR resistance and intermediate resistance to the remaining NNRTIs; F227L (DOR, NVP), L234I (DOR), Y318F (DOR, NVP).

Synergistic combinations: V179D+K103R reduce NVP and EFV susceptibility >10-fold. Y181C+V179F cause high-level ETR and RPV resistance.

ETR genotypic susceptibility score (package insert): Y181IV (3.0); L100I, K101P, Y181C, M230L (2.5); V90I, E138A, V179F, G190S (1.5); A98G, K101EH, V106I, V179DT, G190A (1.0); <2.5 susceptible; 2.5 to 3.0 intermediate; >3.0 high-level. V90I, A98G, V106I, E138A, V179DT, G190A/S have little effect on ETR susceptibility alone.

References: hivdb.stanford.edu/s/nnrtinotes

Major Integrase Inhibitor (INSTI) Resistance Mutations											
	66	92	118	138	140	143	147	148	155	263	
Cons	T	E	G	E	G	Y	S	Q	N	R	
BIC	K	Q	R	KAT	SAC			HRK	H	K	
DTG	K	Q	R	KAT	SAC			HRK	H	K	
EVG	AIK	Q	R	KAT	SAC		G	HRK	H	K	
RAL	AIK	Q	R	KAT	SAC	RC		HRK	H	K	

Bold underline: High-level reduced susceptibility or virological response. **Bold:** Low-level reduced susceptibility or reduced susceptibility or virological response. Plain text: Reduced susceptibility in combination with other INSTI-resistance mutations.

Abbreviations: Bictegravir (BIC), dolutegravir (DTG), elvitegravir (EVG), raltegravir (RAL).

Additional mutations: L74MI, T97A, V151I, E157Q, G163KR are common polymorphic accessory DRMs. H51Y, F121Y, S153YF, S230R are additional nonpolymorphic mutations associated with reduced susceptibility to one or more INSTIs. E92GV, Y143HKSGA, P145S, Q146P, Q148N, V151AL, and N155ST are rare nonpolymorphic IN mutations that reduce RAL and/or EVG susceptibility. Mutations outside of IN in the polypurine tract have been reported to reduce INSTI susceptibility in two persons.

References: hivdb.stanford.edu/s/instinotes

Major Protease Inhibitor (PI) Resistance Mutations													
	32	46	47	48	50	54	76	82	84	88	90		
Cons	V	M	I	G	I	I	L	V	I	N	L		
ATV/r	I	IL	V	VM	L	VTALM		ATFS	V	S	M		
DRV/r	I		VA		V	LM	V	F	V				
LPV/r	I	IL	VA	VM	V	VTALM	V	AFTS	V		M		

Bold underline: High-level reduced susceptibility or virological response. **Bold:** Reduced susceptibility or virological response. Plain text: Reduced susceptibility in combination with other PI-resistance mutations.

Abbreviations: atazanavir (ATV), darunavir (DRV), lopinavir (LPV), '/r' (ritonavir).

Additional mutations: L10F, V11I, K20TV, L23I, L33F, K43T, F53L, Q58E, A71IL, G73STCA, T74P, N83D, and L89V are common nonpolymorphic accessory resistance mutations. L10F, V11IL, L33F, T74P, and L89V are accessory resistance mutations associated with reduced DRV/r susceptibility. D30N and N88D are nonpolymorphic resistance mutations selected by NFV. L10RY, V11L, L24F, M46V, G48ASTLQ, F53Y, I54S, V82CM, I84AC, N88TG are rare nonpolymorphic variants.

Hypersusceptibility: I50L (each PI except ATV); L76V (ATV).

References: hivdb.stanford.edu/s/pinotes

HIV-1 RT and Protease Mutations for Drug-Resistance Surveillance*					
NRTIs		NNRTIs		PIs	
M41	L	L100	I	L23	I
K65	R	K101	E,P	L24	I
D67	N,G,E	K103	N,S	D30	N
T69	D,Ins	V106	M,A	V32	I
K70	R,E	V179	F	M46	I,L
L74	V,I	Y181	C,I,V	I47	V,A
V75	M,T,A,S	Y188	L,H,C	G48	V,M
F77	L	G190	A,S,E	I50	V,L
Y115	F	P225	H	F53	L,Y
F116	Y	M230	L	I54	V,L,M,A,T,S
Q151	M			G73	S,T,C,A
M184	V,I			L76	V
L210	W			V82	A,T,F,S,C,M,L
T215	Y,F,I,S,C,D,V,E			N83	D
K219	Q,E,N,R			I84	V,A,C
				I85	V
				N88	D,S
				L90	M

*Bennett DE, Camacho RJ, Otelea D, et al. Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update, PLoS One 2009;4:e4724.

Reference: hivdb.stanford.edu/s/who